IndiaCatalog.com
Login Signup
IndiaCatalog.com
Home Web Directory Classifieds Yellow Pages Global Directory City Guide News Photo Galleries
Login
Signup
  • Home
  • Global Web Directory
  • Drugs
Biotechnology
Diagnostic Substances
Drug Delivery
Drug Manufacturers - Major
Drug Manufacturers - Other
Drug Related Products
Drugs - Generic

Inspire Pharmaceuticals, Inc.

Inspire Pharmaceuticals, Inc.

Inspire Pharmaceuticals was founded in 1993 and is based in Durham, North Carolina. Inspire Pharmaceuticals, Inc., a biopharmaceutical company, engages in researching, developing, and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. The company offers AzaSite, an azithromycin ophthalmic solution and topical anti-infective; Elestat, an epinastine HCl ophthalmic solution and topical antihistamine for the prevention of ocular itching associated with allergic conjunctivitis; and Restasis, a cyclosporine ophthalmic emulsion for the treatment of dry eye disease in adults and children in the United States. Its product candidates in clinical development include Prolacria, a diquafosol tetrasodium for the treatment of dry eye disease in phase III; denufosol tetrasodium, an inhaled product for the treatment of cystic fibrosis in phase III; AzaSite for the treatment of blepharitis, which is in phase II; and INS115644 and INS117548, which are in phase I clinical trial for the treatment of glaucoma or ocular hypertension. The company has a joint license agreement with Allergan, Inc. to develop and commercialize Prolacria; a license agreement with InSite Vision Incorporated to commercialize AzaSite, as well as other topical anti-infective products containing azithromycin used in the treatment of human ocular or ophthalmic indications primarily in the U.S. and Canada; and a development, license, and supply agreement with Santen Pharmaceutical Co., Ltd. for the development of diquafosol tetrasodium for the therapeutic treatment of ocular surface diseases in Asia.

SkinMedica, Inc.

SkinMedica, Inc.

SkinMedica, Inc. was founded in 1999 and is headquartered in Carlsbad, California. SkinMedica, Inc. operates as a specialty pharmaceutical company that focuses on developing, acquiring, and commercializing products that treat dermatologic conditions and diseases and enhances the appearance of skin. It offers gels for the treatment of mild to moderate atopic dermatitis; creams for the reduction in growth of unwanted facial hair in women; franchises for the treatment of acne; and products for the treatment of hyperpigmentation. The company also provides anti aging products, aesthetic skin care, moisturizers, and sun protection, eye products, as well as facial and sensitive skin cleansers, rejuvenative and acne treatment toners, and skin polishers. It markets and sells prescription pharmaceutical products, and physician-dispensed and non-prescription skin care products primarily to dermatologists and pediatricians.

Renovo plc.

Renovo plc.

Renovo was established in 2000 by Professor Mark Ferguson and Doctor Sharon O'Kane. Renovo had its way, that famous scar on Harry Potter would be gone in no time. The pharmaceutical company develops drug products designed to prevent scarring caused by skin or cosmetic surgeries, eye injuries, adhesions, tendon and ligament damage, and nerve damage (no word yet on if it helps treat the blemishes of boy wizards). Renovo's chief product is Juvista, a trial stage drug that is injected into the edges of wounds to help prevent scars. The company also has three other pre-clinical drug products in development: Juvidex (for scar improvement), Prevascar (scar reduction), and Zesteem (skin healing).

Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc.

Bioniche Life Sciences is seeking its niche in the development of drugs for both humans and animals. The firm has three divisions: Human Health, Animal Health, and Food Safety. The Bioniche Animal Health division sells products to improve livestock breeding and to boost livestock immunity without antibiotics. Bioniche's Food Safety division works to improve food and water quality by developing technology to prevent infections and diseases in animals that are passed on to humans. The company's Bioniche Therapeutics segment is developing pharmaceuticals to help humankind; it focuses on urology, oncology, and immune system disorders.

CytoGenix, Inc.

CytoGenix, Inc.

CytoGenix, Inc. company was founded in 1995 and is based in Houston, Texas. CytoGenix, Inc. operates as a biopharmaceutical company. It focuses on the development and commercialization of its proprietary technologies for identifying and silencing disease causing genes; and expressing proteins for applications, such as vaccines and isolating novel nucleic acid-based anti-microbial compounds. The company’s technologies include gene silencing techniques (ssDNA) applicable to genes from pathogenic organisms or selected genes from a patient to prevent the expression of harmful proteins; a novel, cell free process to produce large quantities of DNA (synDNA) for use in its own products and for sale to other biopharmaceutical or life science companies; and a methodology to isolate and characterize novel DNA-based drugs (Oligogenix) to which harmful bacteria have not developed resistance. Its products under development include SIMPLIVIR, an anti-herpes topical compound; Oligogenix technique based compounds against methicillin and vancomycin resistant staphylococcus aureus; and DNA vaccines for use in humans, poultry, aquaculture, and cattle. The company in collaboration with the United States Department of Agriculture, engages in a project to develop a synDNA based vaccine against brucellosis, a zoonotic disease which is easily transmitted from animals to humans.

Nippon Kayaku Co., Ltd.

Nippon Kayaku Co., Ltd.

Nippon Kayaku Co., Ltd. company is divided into three primary business lines: functional chemicals, pharmaceuticals, and automotive safety parts (airbags, ignition parts). It also manufactures pesticides and herbicides. Its pharmaceuticals segment is focused on producing anti-cancer drugs and immunosuppressants as well as cardiovascular and neurological drugs (brand name and generics). Other products in its divisions include dyes, inflators for automobile airbags, industrial explosives, epoxy resins, and agricultural chemicals. Nippon Kayaku has offices, manufacturing plants, and laboratories in Japan, as well as operations in China, Germany, Taiwan, and the US.

STADA Arzneimittel AG

STADA Arzneimittel AG

STADA Arzneimittel AG (STADA) is a Germany-based company active in the pharmaceutical sector, concentrating on the development and marketing of products with off-patent active pharmaceutical ingredients. The Company’s primary business segments are: Generics, comprised of low-priced and active-ingredient products, and Branded Products, focusing on multisource products that are accessible without active ingredient research. STADA’s generic drugs are marketed by the Group subsidiary, STADApharm GmbH, through a sales network including Austria, Belgium, Bosnia, Portugal and the United Kingdom. Its branded products are distributed internationally as well, in such countries as Bulgaria, the Czech Republic, Denmark, Russia, Thailand and Vietnam. The Company operates through subsidiaries located in Germany, Switzerland, Russia, Macedonia, Serbia, Montenegro, Bulgaria, Romania and Poland, as well as in the United States.

Astex Therapeutics Limited

Astex Therapeutics Limited

Astex Therapeutics (formerly Astex Technology) is working on Pyramids, but on a much, much smaller scale than the Egyptians did. Astex Therapeutics Limited company's Pyramid is a fragment-based drug discovery platform that utilizes X-ray crystallography to develop small molecule drugs. Astex is using the Pyramid platform to develop new therapies for Alzheimer's disease, numerous types of cancers, and chronic inflammation. The company relies in part on a large group of investors for funding. Some of its main investors include Oxford Biosciences, Advent International, Apax, Bayer Schering, and Johnson & Johnson. Astex is collaborating with Novartis andJanssen Pharmaceutica on drugs for the treatment of cancer.

Repros Therapeutics Inc.

Repros Therapeutics Inc.

Repros Therapeutics Inc. was founded in 1987 and is based in The Woodlands, Texas. Repros Therapeutics Inc., a development stage biopharmaceutical company, focuses on the development of oral small molecule drugs for the treatment of male and female reproductive disorders. Its lead drug includes Proellex, a selective blocker of the progesterone receptor, which is in Phase III clinical trials for use as a pre-surgical treatment for women with anemia due to excessive menstrual bleeding associated with uterine fibroids, or anemia associated with uterine fibroids; in Phase III clinical trials for the chronic treatment of symptoms associated with uterine fibroids; and in Phase II clinical trials for the chronic treatment of symptoms associated with endometriosis. The company's product candidates also comprise Androxal, a single isomer of clomiphene citrate, which is in Phase IIb clinical trials for the treatment of low testosterone levels in men, who want to improve or maintain their fertility and/or sperm number and function. In addition, it holds a patent portfolio of phentolamine-based product candidates, including VASOMAX for the treatment of male erectile dysfunction under the Z-Max brand name. The company was formerly known as Zonagen, Inc. and changed its name to Repros Therapeutics Inc. in May 2006 to reflect company's focus on therapeutics for reproductive disorders.

Dendreon Corporation

Dendreon Corporation

Dendreon Corporation, formerly known as Activated Cell Therapy, Inc., was founded in 1992 and is headquartered in Seattle, Washington. Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that improve cancer treatment options for patients. Dendreon’s most advanced product candidate is Provenge (sipuleucel-T), an active cellular immunotherapy that has completed two Phase III trials for the treatment of asymptomatic, metastatic, androgen-independent prostate cancer.

Post a FREE Classified Advertisement

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.

Most Read News

IndiaCatalog News
Iranian oil offered to India at premium to Brent after US sanctions waiver
IndiaCatalog News
LPG supply crisis: No respite for transporters, restaurants in West Bengal
IndiaCatalog News
West Asia war damages over 40 energy assets, risks supply disruption: IEA
IndiaCatalog News
After Zomato, Swiggy raises platform fee by 17% to ₹17.58 per order
IndiaCatalog News
Ukrainian drone strike hits Russia's Primorsk oil port, damages fuel tank

CORPORATE NEWS

HDFC Bank
HDFC Bank
ICICI Bank
ICICI Bank
Ford India Limited
Ford India Limited
Reliance Energy
Reliance Energy
Axis Bank
Axis Bank
Punjab National Bank
Punjab National Bank
Microsoft India (R&D) Pvt. Ltd.
Microsoft India (R&D) Pvt. Ltd.
Lanco Industries
Lanco Industries
IndiaCatalog.com

IndiaCatalog.com is a website brought to you by Portland Technologies to provide directory of Indian websites, News, City Guides and profiles of Indian Businesses. Portland Technologies also provides IT solutions for Small and Medium Businesses in India.


Products

India Web Directory

Global Web Directory

Yellow Pages

Photo Galleries

FREE India Classifieds


Useful links

About us

Advertise

Link to us

Submit a Site

Business Reviews


Contact

Plot #37, Ramnagar Gundu, Hyderabad - 500 044

service@indiacatalog.com

+91-40-23756949


© Copyright: IndiaCatalog.com